Here's Why Avalo Therapeutics (AVTX) is Poised for a Turnaround After Losing 40.4% in 4 WeeksZacks Investment Research • Wednesday
Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business UpdatesGlobeNewsWire • 11/05/26
This Avalo Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For FridayBenzinga • 10/23/26
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 09/29/26
Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 CongressGlobeNewsWire • 09/23/26
Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business UpdatesGlobeNewsWire • 08/06/26
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β AntibodyGlobeNewsWire • 06/16/26
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 05/22/26
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business UpdatesGlobeNewsWire • 05/13/26
This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A BreakoutInvestors Business Daily • 05/06/26
Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 05/05/26
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis SuppurativaGlobeNewsWire • 05/05/26
Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should KnowZacks Investment Research • 04/03/26
Avalo Therapeutics Reports 2025 Financial Results and Recent Business UpdatesGlobeNewsWire • 03/23/26
Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear CaseBenzinga • 02/02/26